Rotavirus gastroenteritis is a highly contagious, acute viral disease that imposes a significant health burden worldwide. In Japan, rotavirus vaccines have been commercially available since 2011 for voluntary vaccination, but vaccine coverage and effectiveness have not been evaluated. In the absence of a vaccination registry in Japan, vaccination coverage in the general population was estimated according to the number of vaccines supplied by the manufacturer, the number of children who received financial support for vaccination, and the size of the target population. Patients with rotavirus gastroenteritis were identified by reviewing the medical records of all children who consulted 6 major hospitals in Saga Prefecture with gastroenteritis symptoms. Vaccination status among these patients was investigated by reviewing their medical records or interviewing their guardians by telephone. Vaccine effectiveness was determined using a screening method. Vaccination coverage increased with time, and it was 2-times higher in municipalities where the vaccination fee was supported. In the 2012/13 season, vaccination coverage in Saga Prefecture was 14.9% whereas the proportion of patients vaccinated was 5.1% among those with clinically diagnosed rotavirus gastroenteritis and 1.9% among those hospitalized for rotavirus gastroenteritis. Thus, vaccine effectiveness was estimated as 69.5% and 88.8%, respectively. This is the first study to evaluate rotavirus vaccination coverage and effectiveness in Japan since vaccination began.
Introduction
Rotavirus is the predominant cause of severe gastroenteritis among infants and young children, with most infections occurring from winter to early spring. Almost every child has been infected with rotavirus at least once by the age of 5 years, with subsequent infections becoming less severe because of increasing immunity. Severe dehydration resulting from rotavirus-induced diarrhea and vomiting can be fatal. In 2008, approximately 453,000 infants or children, mainly in developing countries, were estimated to have died from rotavirus gastroenteritis (RVGE). 1 Although death resulting from rotavirus infection is rare in developed countries, it has been reported that approximately 40-50% of hospitalizations due to infectious gastroenteritis of infants and young children (<5 y of age) are caused by rotavirus. 2 Infants of less than 11 months with RVGE often require intravenous hydration and hospitalization. 3 Moreover, severe complications such as encephalopathy, 4 myocarditis, 5 and sudden unexpected death 6 have been reported.
In Japan, a study estimated that approximately 790,000 children aged 6 y or younger visited pediatric outpatient departments because of RVGE in a year. 7 Furthermore, limited studies indicate an estimated 26,500-78,000 people a year are hospitalized because of RVGE. [8] [9] [10] These estimates indicate the substantial health burden that rotavirus also presents in developed countries.
To date, 2 live oral vaccines, a monovalent human rotavirus vaccine (RV1, Rotarix Ò , GlaxoSmithKline Biologicals) and a pentavalent bovine-human reassortant vaccine (RV5, Rotateq Ò , Merck & Co., Inc.), have been licensed in more than 100 countries. These vaccines were recommended for global use by the World Health Organization in 2009 and had been integrated into national immunization programs in more than 50 countries by April, 2014. 11 After approval, both vaccines showed high effectiveness and safety for RVGE.
According to a systematic review, the effectiveness of vaccines RV1 and RV5 against severe RVGE was 94-71% and 83-75%, respectively, in high-income countries. 12 In Japan, RV1 and RV5 have been commercially available since November 2011 and July 2012, respectively. In large clinical trials, high efficacies against severe RVGE including hospitalization were shown (79-96%). 13, 14 An observational study examining changes in disease burden over time, including seasons before and after the introduction of these vaccines, has been reported in Japan. 15 In Shibata, Niigata Prefecture, Japan, the incidence rates of severe RVGE among children aged less than 3 y were found to be reduced by 71.2%, 47.7%, and 81.1% for 2012, 2013, and 2014 compared with that in 2011 before the vaccine was introduced. 15 Although data regarding the efficacy of the vaccine in clinical trials and the impact of vaccination via an observational study have been reported in Japan, no studies assessing the CONTACT Kaoru Araki abekaoruko1127@yahoo.co.jp current effectiveness of these vaccines have been published. To promote rotavirus vaccination, it is first important to establish the effectiveness of this vaccine since its introduction into Japan. The aim of this study was to investigate retrospectively changes in vaccine coverage and effectiveness since 2011 in Japan using a screening method.
Results
During the 2011/12 and 2012/13 seasons, 38 and 187 children, respectively, were consulted as part of a study of acute gastroenteritis patients. For this target group, the outbreak of disease peaked from March to April. According to the National Epidemiological Surveillance of Infectious Diseases system from the National Institute of Infectious Diseases, this trend correlated with the rotavirus outbreak data reported by a national infection research institute. 16 As shown in Figure 1 , during the 2011/12 season, target patients were limited and no patients with RVGE who had been vaccinated presented. Thus, vaccine effectiveness in the 2011/12 season could not be estimated. In the 2012/13 season, 87 children (46.5%) were diagnosed with RVGE using an immunochromatography kit. Table 1 shows the characteristics of acute gastroenteritis patients in the 2012/13 season: the median age was 11 months (age range: 2-21 months), 109 children (58.3%) were male, and 120 children (64.2%) were inpatients. The median age of the rotavirus positive cases was 13 months with 36 cases (41.4%) being children under 1 y of age. In rotavirus positive cases, severe outcomes requiring intravenous rehydration and hospitalization were more prevalent than in the rotavirus negative cases. Figure 2 shows the change in monthly vaccine coverage following introduction of the vaccine for Saga Prefecture, Saga city, and Ogi city. In all areas, vaccine coverage increased with time (P for trend <0.01). Compared with Saga city, vaccine coverage in Ogi city, which supports the vaccination fee, was approximately 2-times higher and increased more sharply. The vaccine coverage in Saga prefecture during the 2012/13 season was 14.9%. Table 2 shows vaccine coverage in rotavirus-positive cases and in the general population and the effectiveness of vaccination, as determined by a screening method, in the 2012/13 season. Among 87 rotavirus-positive cases, one case (1.1%) was medically examined the day after vaccination and 7 cases (8%) had an unknown vaccination status; these cases were excluded from the analysis. Four children among the remaining 79 cases received vaccine RV1. They were vaccinated with 2 doses (as recommended), and symptoms, such as vomiting and diarrhea, developed at least 1 month after the day of the last inoculation. Vaccine coverage during the 2012/13 season was estimated to be 5.1%. Vaccine coverage for rotavirus-positive cases within 12 months was 6.1% and for more than 12 months was 4.3%. According to these results, the effectiveness of vaccination for preventing RVGE in Saga for the 2012/13 season was estimated to be 69.5% (95% confidence interval [CI]: 37.1-98.9%). Vaccine effectiveness within 12 months was 71.7%, compared with 55.4% for more than 12 months. Additionally, the effectiveness in terms of reducing hospitalization owing to RVGE was estimated to be 88.8% (95% CI: 34.3-100.0%). 
Discussion
This is the first study to investigate the effectiveness of the rotavirus vaccine during the first 2 y after it was introduced into Japan. The effectiveness of the vaccine in protecting against RVGE, as determined by the screening method, was estimated to be 69.5%. This level of efficacy was similar to that reported by a previous clinical trial (75-79% for RVGE, 96% for hospitalization owing to RVGE), 13, 14 confirming the effectiveness of the rotavirus vaccine in Japan.
Most analyses of rotavirus vaccine effectiveness following its introduction have been case-control studies, reporting rates of 80%-90% effectiveness. According to reports from developed countries (Spain, 17, 18 Germany, 19 Taiwan, 20 Portugal, 21 the United States of America, 22 and Belgium 23 ), the effectiveness of the vaccine against severe RVGE requiring hospitalization was higher than that against cases not requiring hospitalization. An investigation in 2010 and 2011 in the United States of America, where the rotavirus vaccine was being used routinely, reported that the effectiveness of the vaccine against hospitalization owing to RVGE was 91% (95% CI: 80%-95%). 22 Similarly, in Taiwan, where rotavirus vaccination was voluntary, the effectiveness against severe RVGE was 90.4% (95% CI: 70.3-98.1%). 20 The effectiveness of the vaccine against hospital visits owing to RVGE was 83.7% (95% CI: 73.9%-89.8%) in Portugal 21 and 83.5% (95% CI: 45.5%-99.7%) in Spain. 18 Although, in our study, vaccine effectiveness against the total number of RVGE cases was estimated to be slightly lower compared with the results of previous clinical trials, 13, 14 the effectiveness of the vaccine against hospitalization for RVGE was found to be almost the same.
The current study was conducted using a screening method. Vaccine effectiveness determined by this method was similar to the findings from case-control studies and will be helpful in verifying estimates in clinical trials. In Nicaragua, 2 case-control studies for rotavirus effectiveness were conducted. 24, 25 The first study was conducted by the United States Centers for Disease Control and Prevention from 2007 to 2008. The vaccine effectiveness in 2008 against severe RVGE in children aged 8 to 11 months was 69% (95% CI: 24%-87%). 24 The second study was coordinated by the Ministry of Health in Nicaragua and Merck and Co., Inc. from 2007 to 2009. Using the data from 2008, the vaccine effectiveness to prevent severe RVGE was 92% (95% CI: 79%-97%) for cases <12 months of age. 25 Cardellino.A et al employed the screening method using these data in 2008 and estimated that vaccine effectiveness was 72% (95% CI: 62%-83%) to 92% (95% CI: 78%-100%). The results were relatively consistent with those of their 2 cases-control studies. 26 The screening method is therefore reliably consistent with the data from case-control studies.
The effectiveness of the vaccine among 12-22 months was lower than that among under 12 months, indicating the possibility that the effect of the vaccine lessened with time postvaccination. However, the present study was conducted just after the introduction of the vaccine and the proportion of the population vaccinated (PPV) after 1 y was low; therefore, the effectiveness of the vaccine may have been underestimated. There are few reports about the effect of lasting immunity after rotavirus vaccination, but a follow-up survey of RV1 in high income countries of Asia reported that the protective effects against severe cases lasted at least 3 y after vaccination. Interestingly, the rise in vaccination coverage since approval of the rotavirus vaccine was higher in areas where the vaccination fee was supported. It has previously been reported that financial assistance and information are necessary to motivate parents to voluntarily vaccinate their children in Japan. 28 It is possible that in areas in which financial support for vaccination is available, more information is publicized regarding the vaccine, both of which may contribute to the observed rise in vaccine coverage.
This study had some limitations. First, vaccine coverage was calculated by the number of births and the number of shipments of the vaccine; therefore, the PPV is an estimate. This estimation does not take into account infants who died after birth, those who were unable to be vaccinated because of underlying diseases, and those who only received one dose of the vaccine and were therefore not fully protected. In April, 2013, the Ministry of Health, Labour and Welfare published rotavirus vaccine coverage data by prefecture. Vaccine coverage in Saga Prefecture was 28%, which was in accordance with our findings for the same period, 29.9%. Second, using the screening method, estimations of vaccine effectiveness may fluctuate when the PPV and the proportion of cases vaccinated (PCV) are too low. 29 In the current study, vaccine coverage was estimated just after the introduction of the vaccine and would therefore include a period of time when vaccine coverage would be low. Because this variability in the PPV would be high, vaccine effectiveness may consequently be underestimated. Additionally, because this study was based on data from one prefecture, the limited population size may confer a degree of error in the PCV. Third, in this study the target hospitals were limited to only higher order medical institutions having hospitalization facilities and emergency lifesaving centers. The effectiveness of the vaccine against mild RVGE could therefore not be estimated because almost all of the children with initial symptoms of this disease would have presented at primary facilities. However, the primary purpose of the rotavirus vaccine is to prevent hospitalization and death caused by serious vomiting and diarrhea. The effectiveness in these situations was evaluated in this study. Finally, the screening method is a relatively simple and effective method for determining vaccine effectiveness, but does not take into account confounding factors such as incomplete vaccination or other underlying diseases. It is now necessary to confirm the authenticity of our data using a more elaborate method such as a case-control study.
In conclusion, this is the first study to evaluate the effectiveness of the rotavirus vaccine by the screening method in Japan. Vaccine coverage increased with time following introduction of the vaccine and the effectiveness of the vaccine was estimated to be 69.5% for clinically diagnosed RVGE and 88.8% for hospitalized RVGE cases. These results support promotion of the rotavirus vaccination program in Japan.
Patients and methods

Investigation area
The investigation was conducted in Saga Prefecture in Japan. This area has a stable population of approximately 850,000 inhabitants, and approximately 7,500 babies are born each year. Rotavirus vaccine is voluntary in Japan and costs 13,000-15,000 Japanese yen per inoculation. Among municipalities in this area, only Ogi city has public money to assist with the vaccine program, contributing 5,000 yen per inoculation. We requested the cooperation of 6 major hospitals with pediatric outpatient departments and hospitalization facilities in Saga (Saga University Hospital, Saga-Ken Medical Centre Koseikan, Saga National Hospital, Saga Chubu Hospital, Ureshino Medical Center, and Higashisaga Hospital). These are higher order medical institutions treating the seriously ill including those with acute gastroenteritis. The survey protocol was approved by the Ethical Committee of Saga University Faculty of Medicine, Saga-Ken Medical Centre Koseikan, and Saga National Hospital. Other hospitals were approved as cooperation facilities of Saga University Faculty of Medicine. Vaccination information, including whether a child had received the rotavirus vaccine, the type of vaccine, the number of doses, the date of the last dose, and the outcome (oral medication, intravenous rehydration to correct dehydration, admission), was usually obtained from their medical records in the hospital in cooperation with their pediatrician. If the vaccination status was not available in their medical record, it was obtained by telephone interview with their guardian. Children administered the last dose of vaccine within 14 d before the onset of gastroenteritis were excluded because of development of a protective immune response.
Rotavirus gastroenteritis patients and vaccine coverage
Vaccine coverage of the general population
Because there is no register for national vaccination in Japan, data regarding rotavirus vaccine coverage in the general population are not readily available. We therefore obtained the number of rotavirus vaccines shipped monthly by pharmaceutical companies (GlaxoSmithKline and Merck & Co.) into Saga Prefecture and divided this by the number of doses (RV1: 2, RV5: 3). Thus, we estimated the number of people that received the vaccine in each month. This was then divided by the number of monthly births taken from the demographic data for Saga Prefecture and the cities of Saga and Ogi. In this way, we estimated the monthly vaccine coverage, as shown in Figure 2 . Additionally, we obtained information for Ogi city regarding financial assistance for the vaccine.
Statistical analysis
The SAS statistical software package (Ver. 9.3 for Windows; SAS Institute, Cary, NC, USA) and Microsoft Excel (version 2010, Microsoft Japan) were used for statistical analysis. To compare the characteristics of gastroenteritis cases between rotavirus-positive cases and those negative cases, we used the x 2 test for categorical variables and the Wilcoxon rank sum test for continuous variables. The trend of monthly increase of vaccine coverage was tested by a logistic regression model, using PROC LOGISTIC in SAS.
The effectiveness of the rotavirus vaccine was estimated by the screening method using the Farrington algorithm, according to the following formula. 30 Vaccine effectiveness
PCV is the proportion of cases vaccinated, which means the proportion of vaccinated among rotavirus-positive cases. The exact 95% confidence interval (CI) for the PCV was constructed by using the BINOMIAL option in the EXACT statement of PROC FREQ in SAS. PPV is the proportion of the population vaccinated, which means vaccination coverage of the general population. We employed the person-time method to derive PPV (i.e., person-time during the investigation period in the vaccinated divided by that in both the vaccinated and unvaccinated) because the target population aged over time. Personmonths accumulated in each stratum by vaccination status (and age category [2-11 or 12-21 months] in age-stratified analysis) in the target population was calculated for the 8 month period in the 2012/13 season. For example, in age-stratified analysis (Table 2 ), a child who was born in May 2012 contributed 6 person-months to the age category of 2-11 months and 2 person-months to that of 12-21 months, for the above 8 month period. A P value of less than 0.05 was considered statistically significant, and for vaccine effectiveness, its estimate was regarded as significant if its 95% CI did not include the null value (0). 
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